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Abstract
Strategies to reduce rates of Clostridium difﬁcile infection (CDI) generally recommend isolation or cohorting of active cases and the
reduced use of cephalosporin and quinolone antibiotics. Data supporting these recommendations come predominantly from the setting
of epidemic disease caused by ribotype 027 strains. We introduced an initiative involving a restrictive antibiotic policy and a CDI-cohort
ward at an acute, 820-bed teaching hospital where ribotype 027 strains account for only one quarter of all CDI cases. Antibiotic use
and monthly CDI cases in the 12 months before and the 15 months after the initiative were compared using an interrupted time series
analysis and segmented regression analysis. The initiative resulted in a reduced level of cephalosporin and quinolone use (22.0% and
38.7%, respectively, both p <0.001) and changes in the trends of antibiotic use such that cephalosporin use decreased by an additional
62.1 deﬁned daily doses (DDD) per month (p <0.001) and antipseudomonal penicillin use increased by 20.7 DDD per month
(p = 0.011). There were no signiﬁcant changes in doxycycline or carbapenem use. Although the number of CDI cases each month was
falling before the intervention, there was a signiﬁcant increase in the rate of reduction after the intervention from 3% to 8% per month
(0.92, 95% CI 0.86–0.99, p = 0.03). During the study period, there was no change in the proportion of cases having their onset in the
community, nor in the proportion of ribotype 027 cases. CDI cohorting and restriction of cephalosporin and quinolone use are effective
in reducing CDI cases in a setting where ribotype 027 is endemic.
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Introduction
Clostridium difﬁcile has emerged as a major nosocomial patho-
gen. Numerous reports from North America and Europe
have described increases in incidence and severity of
C. difﬁcile infection (CDI) over the last 10 years [1–3]. There
were over 290 000 hospitalizations related to CDI in the
USA in 2005 and the UK Health protection agency recorded
over 40 000 CDI cases in 2008 [4]. CDI severity appears to
have increased as new strains, in particular those of restric-
tion endonuclease (REA) type BI/ribotype 027, have emerged
[5,6]. Several features have been implicated in the emergence
and virulence of BI/027 strains, including the presence of
a binary toxin gene, a deletion in the regulatory tcdC
gene, resistance to quinolone antibiotics and hypersporu-
lation [7].
The most important modiﬁable risk factors for developing
CDI are antibiotic exposure, particularly to cephalosporin
and quinolone antibiotics, and contact with patients with
CDI or their caregivers and environment [8].
Consequently, recommendations for the control of CDI
frequently involve antibiotic policies restricting the use of
these antibiotic classes and enhanced efforts to isolate or
cohort patients with active CDI [9,10]. In January 2008, we
introduced an initiative in our hospital involving a new antibi-
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otic policy restricting cephalosporin and quinolone use and
the opening of a ward speciﬁcally for the cohorting of
patients with CDI. In the present study, we report the
impact of this on antibiotic use and the frequency of CDI.
Materials and Methods
Setting
Brighton and Sussex University Hospitals NHS Trust
(BSUHT) is an 820-bed teaching hospital providing acute sec-
ondary care services to 500 000 people in Brighton, Hove
and Mid-Sussex and tertiary services (cardiothoracic, oncol-
ogy and renal) to a population of approximately two million.
Rationale
We launched the initiative in response to recommendations
made by the UK Department of Health Healthcare Commis-
sion after an inspection of our hospital in October 2007.
Population and case deﬁnitions
Table 1 gives details of the population and case deﬁnitions
throughout the study. All patients testing positive for C. difﬁ-
cile toxins A or B were included in the study. The laboratory
does not test repeat samples from the same patient within
30 days of a previous positive sample.
Intervention
The initiative introduced had two main components: (i) the
opening of an 11-bed cohort ward for patients with CDI and
(ii) a new antibiotic policy restricting the use of cephalospo-
rins and quinolones. Although these measures were intro-
duced simultaneously, efforts to improve compliance with
good infection control practice and surveillance were ongo-
ing throughout the study period. Throughout the study, alco-
hol gels were used as the primary agent for hand hygiene
with hand-washing advised after contact with CDI cases.
The cohorting ward was speciﬁcally for patients with CDI.
Patients testing positive for CDI who still had on-going
diarrhoea were transferred to the cohort ward on the same
day. The ward had its own nursing staff and all patients
admitted to the ward were transferred to the care of the
infectious diseases team. All staff working on the ward wore
scrubs and put on a new apron and gloves between each
patient contact. A small minority of CDI patients had health
needs, most usually surgical or high-dependency, which pre-
vented transfer to the ward; however, all patients eligible for
transfer to the ward were accommodated there.
The new antibiotic policy replaced cephalosporin and
quinolone antibiotics with aminopenicillin or antipseudomon-
al penicillins. Examples of how this was achieved are given
in Table 1. The policy was widely publicised in the hospital
but no speciﬁc measures were put in place to enforce
compliance.
Assessment of impact
A retrospective interrupted time series (ITS) analysis looking
at antibiotic use and number of CDI cases was conducted,
with the pre-intervention phase being January to December
2007 and the post-intervention phase being January 2008 to
March 2009. Data were gathered from information routinely
recorded by the infection control and pharmacy depart-
ments. Bed occupancy data were obtained from the hospi-
tal’s clinical information unit.
Outcomes
The primary outcomes were: (i) change in use of targeted
antibiotics and (ii) the reduction in number of CDI cases. To
determine changes in use of untargeted antibiotics we also
gathered data on use of aminopenicillins, antipseudomonal
TABLE 1. Population, clinical setting, nature and timing of interventions
Setting: 820–bed acute teaching hospital with
a rate of CDI close to the UK average
Dates: 1 January 2007 to 31 March 2009 Population characteristics: all in-patients from whom a
diarrhoeal stool tested positive for Clostridium difﬁcile toxin
>72 h after admission. Total bed days during the study
period
Intervention: A package of measures to combat CDI, speciﬁcally a cephalosporin- and quinolone-restrictive antibiotic policy and a cohort ward for CDI patients
Antibiotic policy Isolation policy
Phase 1: 12 months (1 January 2007 to 31
December 2007)
Nonrestrictive antibiotic guidelines All patients with diarrhoea to go into side-rooms, with
standard isolation
Phase 2: 15 months (1 January 2008 to 31
March 2009)
Cephalosporin and quinolone restrictive All eligible patients to go to CDI cohort ward within 24 h of
CDI diagnosis until discharge
Nonrestrictive antibiotic guidelines (phase 1): community-acquired pneumonia; cefuroxime + clarithromycin, cellulitis; ceftriaxone, hospital-acquired pneumonia; ciproﬂoxacin
Restrictive antibiotic guidelines (phase 2): e.g. community-acquired pneumonia; amoxicillin + clarithromycin, cellulitis; benzylpenicillin and ﬂucloxacillin, hospital-acquired
pneumonia; piperacillin-tazobatam.
Case deﬁnition of CDI (both phases): a patient from whom a liquid stool tested positive for C. difﬁcile toxin A or B Case deﬁnition of hospital-associated CDI (both phases) :
onset more than 72 h after admission to hospital or within 72 h after discharge.
Detail of the cohorting intervention. The cohorting ward was only for CDI patients and had dedicated nursing staff. All patients were looked after by one medical team. All
staff wore scrubs and changed gloves and aprons between all patient contacts. All patients eligible for cohorting on the ward were admitted there during the study period.
CDI, Clostridium difﬁcile infection.
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penicillins and carbapenems. For controls, we gathered data
on use of doxycycline (an antibiotic unlikely to be affected by
the intervention), monthly admissions and bed occupancy.
Potential confounders
Data were obtained on number of admissions and bed days
each month but not on compliance with infection control
practices such as hand cleaning. There were no major
changes in policies related to environmental cleaning (chlo-
rine dioxide solution used for decontamination) or infection
control education or monitoring during the study period.
There were no changes in laboratory methods for handling
samples during the study time, although the laboratory
switched from working 5–7 days per week in July 2008.
Microbiological analysis
Throughout the study, hospital policy was that patients
with diarrhoea should have stool sent for microbiological
analysis and that all liquid stool samples received by the
microbiology laboratory were tested for C. difﬁcile toxins A
and B using Premier toxin A and B ELISA (Meridian Biosci-
ence, Cincinnati, OH, USA). Runs were performed once
each day. Formed stools were not tested. In each phase of
the study, stool samples from a subset of patients (consec-
utive patients between June and November 2007 and
March to August 2008) who were involved in a separate
study of the relationship between ribotype and outcome
were frozen at )80C and subsequently cultured for C. dif-
ﬁcile (R.M. Alden Research Laboratory, Culver City, CA,
USA). C. difﬁcile isolates underwent REA in the laboratory
of D. Gerding (Hines Veterans Affairs Hospital, Hines, IL,
USA).
Statistical analysis
The effect of the intervention on antibiotic usage was analy-
sed using segmented regression analysis to compare the
pre- and post-intervention phases in terms of level both and
linear trend. The ordinary least squares segmented regres-
sion model is given by the equation:
Yt ¼ b0 þ b1 montht þ b2  interventiont
þ b3 month after interventiont þ et
where Yt is the outcome in month t, montht is the number
of months from the start of the study period, interven-
tiont = 0 before the intervention and 1 after the interven-
tion, month after interventiont is the number of months
after the intervention and is equal to zero before the inter-
vention, b0 is the baseline level of the outcome at the start
of the study period, b1 is the pre-intervention trend, b2 is
the change in post intervention level, b3 is the change in post
intervention trend and t is the error. The errors are
assumed to be independent. This assumption was tested
using the Durbin–Watson statistic. If autocorrelation in the
errors was detected, this was adjusted for by including an
autoregressive term in the regression model.
A Poisson segmented regression model was used for the
number of CDI cases which was assumed to follow a Poisson
distribution with mean number of cases in month t, lt, given
by:
InðltÞ ¼ b0 þ b1 montht þ b2  interventiont
þ b3 month after intervention
Again, the residuals were tested for autocorrelation. Data
were analysed using SPSS 15.0.0 (SPSS Inc., Chicago, IL, USA)
and GraphPad Prism 5 (GraphPad Software Inc., San Diego,
CA, USA).
Ethical considerations
Data on antibiotic use and CDI cases were collected as part
of the infection control team’s routine clinical governance
activity. All data used in the study were anonymized, rou-
tinely collected data. In keeping with our institution’s policy
on governance activity, the study was not subjected to for-
mal ethical review.
Results
Antibiotic use
The impact of the intervention on antibiotic use is described
in Fig. 1 and Table 2. There was evidence of ﬁrst-order auto-
correlation in the residuals from the regression on cephalo-
sporins, and therefore a term for the lagged residuals was
included in the model. There was no signiﬁcant residual
autocorrelation for the other antibiotics.
Before the intervention, the only signiﬁcant trend in antibi-
otic use was a gradual increase in carbapenem use, which
continued after the intervention. After the intervention,
there were signiﬁcant decreases in the level of use of cepha-
losporins (22.0%) and quinolones (38.7%) (both p <0.001).
There were also signiﬁcant changes in the trends for cepha-
losporins and antipseudomonal penicillins so that use of
cephalosporins decreased by an additional 62.1 deﬁned daily
doses (DDD) per month (p <0.001) and antipseudomonal
penicillins increased by 20.7 DDD per month (p ¼ 0.011).
The level of aminopenicillin use also appeared to increase
after the intervention, although this did not reach statistical
signiﬁcance. There were no signiﬁcant changes in level or
trend for doxycycline use.
CMI Price et al. Clostridium difﬁcile: an interrupted time series 1299
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1297–1302
CDI cases
In the pre-intervention phase, there were 353 CDI cases and
82 887 admissions to the hospital compared to 258 CDI
cases and 117 358 admissions in the post-intervention phase.
The CDI rate was 1.30 cases/1000 bed days in the pre-inter-
vention period and 0.69 cases/1000 bed days in the post-
intervention period. In the segmented Poisson regression
analysis of the total number of CDI cases, the residuals
showed no evidence of autocorrelation and no adjustment
was made. Prior to the intervention, there was a signiﬁcant
downward trend, with the number of cases decreasing by 3%
per month [multiplicative factor of exp()0.032) = 0.97 per
month (p 0.04, 95% CI 0.94–1.00)]. After the intervention,
there was a signiﬁcant change, with the number of cases
decreasing by 8% per month (multiplicative decrease per
month was exp()0.032) · exp()0.047) = 0.92 (p 0.03, 95%
CI 0.86–0.99). The goodness of ﬁt of the model was ade-
quate (v2 = 31.5, p 0.11).
The proportion of CDI cases each month with an onset in
the community varied between 0.29 and 0.73. There was no
signiﬁcant change in the proportion of community cases
before and after the intervention.
Microbiological analysis
C. difﬁcile was cultured from 68 and 59 cases in phases 1 and
2 of the study, respectively. The proportion of cases caused
by different REA types is shown in Table 3. Ribotypes are
inferred from Killgore et al. [11]. In both phases, REA type/
ribotype strains DH/106 and BI/027 predominated. There
was no signiﬁcant difference in the frequency of different
strain types between the study phases (p 0.17).
Discussion
We have reported the impact of an initiative to combat CDI
that was associated with a sustained reduction in the number
of CDI cases at our hospital. We have described the inter-
vention and analysis in line with the ORION statement on
reporting intervention studies in nosocomial infection [12].
We have chosen to analyse the impact of the intervention
on the total number of CDI cases per month rather than
correcting for number of admissions or bed occupancy
because our CDI patients are almost exclusively very elderly
and have extensive health care contact, even if their CDI
symptoms had an onset outside hospital. Consequently, it
does not appear to be appropriate to either exclude the
community-onset cases from analysis or to correct the total
case number for our hospital activity. Nevertheless, because
the burden of CDI is more commonly presented as rate per
FIG. 1. Monthly antibiotic use (deﬁned daily doses), Clostridium difﬁ-
cile infection (CDI) rate for nosocomial cases, total number of CDI
cases and bed days between January 2007 and March 2009.
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10000 bed days for hospital-onset disease, we also provide
these data in Fig. 1.
A major challenge for any study which, like ours, attempts
to assess the impact of a healthcare-associated infection
intervention is to be certain that any changes observed are
truly accounted for by the intervention. When we intro-
duced the initiative in January 2008, we were already making
considerable efforts to improve infection control practice
and this is the likely explanation for the downward trend in
CDI cases before the intervention. Recent guidelines in the
UK and elsewhere describe wide-ranging measures to com-
bat CDI but, arguably, the two measures most likely to
change practice are enhanced isolation and restriction of
cephalosporin and quinolone use; precisely the measures we
introduced [9].
These measures were introduced simultaneously in our
hospital and no other signiﬁcant changes in practice likely to
impact on C. difﬁcile transmission were made at this time.
Our demonstration of a statistically robust change in CDI
rates after the intervention supports the efﬁcacy of enhanced
isolation and antibiotic restriction in reducing CDI. Because
the two elements of our intervention were introduced
together, our data do not allow us to distinguish the relative
impact of each. A further limitation of the present study is
that we have not been able to assess the potential for
changes in antibiotic policy to cause harm in terms of either
changing patterns of resistance or adverse clinical outcomes.
Neither have we assessed the costs of the intervention.
However, given the relative paucity of data supporting the
efﬁcacy of cohort wards and antibiotic restriction in control-
ling CDI, we feel that real-life clinical data such as ours are
important.
Several previous studies have assessed the impact of infec-
tion control strategies on CDI. Two recent North American
studies conducted in the setting of epidemic spread of BI/027
strains demonstrated a reduction in CDI incidence associ-
ated with restriction of high-risk antibiotics, both alone and
as part of a ‘bundle’ of measures [13,14]. Similarly, Debast
et al. [15] demonstrated the efﬁcacy of a ‘bundle’ approach
in a Dutch hospital, also in the context of an epidemic of BI/
027 disease.
In the UK, the epidemiology of C. difﬁcile has involved the
progressive replacement of J/001 strains by DH/106 and BI/
027 strains rather than the epidemic emergence of BI/027
that has been seen elsewhere [16]. Our data are therefore
very typical of the UK, demonstrating the co-existence of BI/
027 and DH/106 strains in our patient population. Our data
demonstrate no increase in ribotype 027 over the time per-
iod of this study. Although our sample size is small, the data
obtained do not suggest that our intervention has affected
BI/027 strains differentially. This may be because DH/106
strains, which are uncommon outside the UK, are, similar to
BI/027 strains, usually resistant to quinolone antibiotics [16].
Fowler et al. [17] reported that the control of broad-spec-
trum antibiotic use was effective in reducing CDI in another
UK acute hospital. That study did not contain any strain anal-
ysis and was conduced before BI/027 strains became estab-
lished in the UK.
The present study also differs from previous studies in
that we have observed a reduction in both hospital- and
TABLE 2 Antibiotic use before and after the intervention. The effect of the intervention on antibiotic usage (expressed as
deﬁned daily doses) was analysed using segmented regression analysis to compare the pre- and post-intervention phases in
terms of level both and linear trend
Pre-intervention Post-intervention change
Antibiotic Level Trend p-value Level p-value Trend p-value
Cephalosporins 2703 (2553, 2852)a 2.072 ()18.44, 22.58)a 0.836 )594.2 ()786.3, )402.1)a <0.001 )62.14 ()86.73, )37.55)a <0.001
Quinolones 4105 (3592, 4618) )3.43 ()73.18, 66.32) 0.920 )1588 ()2229, )947.2) <0.001 )69.33 ()155.1, 16.40) 0.108
Aminopenicillins 6527 (5401, 7652) )3.64 ()156.6, 149.3) 0.961 922.2 ()482.7, 2327) 0.188 138.5 ()49.51, 326.4) 0.141
Antipseudomonal Penicillins 246.1 (154.1, 338.1) 1.45 ()11.05, 13.95) 0.813 106.2 ()8.626, 221.1) 0.068 20.67 (5.300, 36.03) 0.011
Doxycycline 1744 (1128, 2360) 25.78 ()57.95, 109.5) 0.531 )74.22 ()843.3, 694.9) 0.844 13.04 ()89.87, 116.0) 0.796
Carbapenems 212.2 (97.9, 326.5) 17.86 (2.33, 33.39) 0.026 )64.70 ()207.4, 77.95) 0.36 )0.279 ()19.37, 18.81) 0.976
95% conﬁdence intervals are given in parentheses.
aAdjusted for ﬁrst-order autocorrelation.
TABLE 3. Frequency of Clostridium difﬁcile strain types
Phase 1 Phase 2
DH/106 25 (36.8) 26 (44.1)
BI/027 19 (27.9) 15 (25.4)
G/002 6 (8.8) 1 (1.7)
J/001 5 (7.4) 1 (1.7)
Other 13 (19.1) 16 (27.1)
Total 68 (100) 59 (100)
Ribotypes are inferred from restriction endonuclease type according to Killgore
et al. [11]. Number and (%) of each type are shown. No signiﬁcant differences
exist in the proportion of cases caused by each strain type in each phase of the
study (p ¼ 0.17).
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community-onset CDI. It is possible that this is explained by
changes in infection control or antibiotic prescribing in pri-
mary care at the same time as our intervention. This is unli-
kely because no speciﬁc infection control interventions were
made in the community during the study period. It is more
likely that, in an endemic setting where CDI affects, almost
exclusively, very elderly patients with extensive health care
contact, infection control interventions in secondary care
impact on CDI presenting in both primary and secondary
care. This further suggests that interventions in primary care,
particularly targeting antibiotic prescribing, should impact on
both hospital and community onset CDI.
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